[Form 3] bioAffinity Technologies, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

bioAffinity Technologies (BIAF) Form 3 — initial ownership disclosure. John J. Oppenheimer, listed as a Director, filed an initial Form 3 reporting that no securities are beneficially owned by him as of the event date 08/12/2025. The form shows the reporting relationship, the issuer symbol BIAF, and a signature dated 09/25/2025.

Positive

• Initial disclosure filed for a reported insider role, satisfying Section 16 reporting requirements.
• Clear statement that no securities are beneficially owned, providing unambiguous disclosure.

Negative

• Reporting director holds no beneficial securities according to this Form 3, limiting observable insider alignment with shareholders.

Insights

Financial Analyst

TL;DR: Initial disclosure filed shows zero beneficial ownership, a neutral compliance event with limited market impact.

The filing is an initial Section 16 report for a newly reported insider role. It conveys factual items only: reporting person identity, director status, event date 08/12/2025, and that "No securities are beneficially owned." For investors this is informational rather than operational: there are no transaction details, no holdings to model, and no compensation or option awards disclosed. Impact on valuation or governance is minimal based solely on this form.

Corporate Governance Expert

TL;DR: A governance disclosure showing a director with no reported holdings; notable for transparency but not materially impactful alone.

The Form 3 documents compliance with Section 16 filing requirements and identifies John J. Oppenheimer as a Director of bioAffinity Technologies, Inc. It explicitly states "No securities are beneficially owned." From a governance perspective, the form confirms disclosure practices are being followed. The filing does not include equity grants, options, or indirect ownership, so it provides no evidence of alignment via ownership or potential conflicts to assess.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Oppenheimer John J.

(Last) (First) (Middle)

C/O BIOAFFINITY TECHNOLOGIES, INC.,

3300 NACOGDOCHES ROAD, SUITE 216

(Street)

SAN ANTONIO, TX 78217

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2025

3. Issuer Name and Ticker or Trading Symbol
bioAffinity Technologies, Inc. [ BIAF ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ John J. Oppenheimer	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did John J. Oppenheimer report on Form 3 for bioAffinity Technologies (BIAF)?

He reported his status as a Director and stated that no securities are beneficially owned as of the event date 08/12/2025.

When is the event date and signature date on the Form 3 for BIAF?

The event date is 08/12/2025 and the form is signed on 09/25/2025.

Does the Form 3 disclose any derivative securities or options for BIAF insider?

No. The filing explicitly states No securities are beneficially owned and lists no derivative or non‑derivative holdings.

Is this Form 3 an amendment or a joint filing?

No. The form indicates it is an initial filing by one reporting person and does not list an amendment date.

What is the ticker symbol and issuer named on the Form 3?

The issuer is bioAffinity Technologies, Inc. with ticker BIAF.